JMP Securities analyst Andrew Boone reiterated a Buy rating on Fiverr International (FVRR – Research Report) on September 9 and set a price target of $50.00. The company’s shares closed last Friday at $36.67.
According to TipRanks, Boone is an analyst with an average return of -20.3% and a 23.08% success rate. Boone covers the Technology sector, focusing on stocks such as Shopify, Twitter, and Wix.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Fiverr International with a $44.00 average price target, which is a 19.99% upside from current levels. In a report released on August 25, Piper Sandler also maintained a Buy rating on the stock with a $50.00 price target.
Based on Fiverr International’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $85.01 million and a GAAP net loss of $41.86 million. In comparison, last year the company earned a revenue of $75.26 million and had a GAAP net loss of $13.3 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Fiverr International Ltd. develops an e-commerce platform that allows the people to buy and sell digital services. It operates through the following geographical segments: U.S., Europe, Asia Pacific, Rest of the World, and Israel. The firm offers digital marketing, graphics and design, video and animation, writing and translation, and music and audio. The company was founded by Micha Kaufman and Shai Wininger in 2009 and is headquartered in Tel Aviv, Israel.
Read More on FVRR:
- Analysts Are Bullish on Top Consumer Goods Stocks: General Motors (GM), Mattel (MAT)
- Analysts Are Bullish on These Materials Stocks: G Mining Ventures (GMINF), Limoneira Co (LMNR)
- Analysts Offer Insights on Healthcare Companies: Cytokinetics (CYTK) and Adaptimmune Therapeutics (ADAP)
- Mizuho Securities Keeps Their Hold Rating on Adaptimmune Therapeutics (ADAP)
- Maxim Group Sticks to Its Buy Rating for StealthGas (GASS)